Abstract
Stroma-leukemia interactions mediated by CXCR4, CD44, VLA4, and their respective ligands contribute to therapy resistance in FLT3-ITD-mutated acute myelogenous leukemia (AML). We conducted a phase 1 study with the combination of sorafenib (a FLT3-ITD inhibitor), plerixafor (a SDF-1/CXCR4 inhibitor), and G-CSF (that cleaves SDF-1, CD44, and VLA4). Twenty-eight patients with relapsed/refractory FLT3-ITD-mutated AML were enrolled from December 2010 to December 2013 at three dose levels of sorafenib (400, 600, and 800 mg twice daily) and G-CSF and plerixafor were administered every other day for seven doses starting on day one. Sorafenib 800 mg twice daily was selected for the expansion phase. While no dose-limiting toxicities (DLT) were encountered in the four-week DLT window, hand-foot syndrome and rash were seen beyond the DLT window, which required dose reductions in most patients. The response rate was 36% (complete response (CR) = 4, complete remission with incomplete platelet recovery (CRp) = 4, complete remission with incomplete hematologic recovery (CRi) = 1, and partial response (PR) = 1) for the intention to treat population. Treatment resulted in 58.4 and 47 mean fold mobilization of blasts and CD34 /38- stem/progenitor...Continue Reading
References
Apr 24, 1999·Leukemia·H EngelM Andreeff
Aug 25, 2001·Blood·J P LévesqueP J Simmons
Jan 18, 2003·The Journal of Clinical Investigation·Jean-Pierre LévesqueLinda J Bendall
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Apr 1, 2004·Blood·Elwin J C RomboutsRob E Ploemacher
Dec 25, 2004·Blood·Seiji FukudaLouis M Pelus
Jul 26, 2006·Experimental Hematology·Seiji Fukuda, Louis M Pelus
Oct 16, 2007·Cancer Cell·Benjamin H LeeD Gary Gilliland
Jan 31, 2008·Journal of the National Cancer Institute·Weiguo ZhangMichael Andreeff
Oct 29, 2008·Blood·Zhihong ZengMarina Konopleva
Oct 30, 2008·Blood·Michael FieglMichael Andreeff
Aug 19, 2009·The Journal of Experimental Medicine·Rebekka GrundlerJuerg Schwaller
Dec 29, 2009·Experimental Hematology·Angela JacobiSebastian Brenner
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Farhad RavandiHagop M Kantarjian
Oct 19, 2010·Haematologica·Gautam BorthakurJorge E Cortes
Apr 28, 2011·Cancer·Fabio P S SantosGautam Borthakur
Feb 7, 2012·Blood·Geoffrey L UyJohn F DiPersio
Apr 17, 2012·Nature·Catherine C SmithNeil P Shah
Apr 25, 2013·Blood·Farhad RavandiMark Levis
May 17, 2013·The Journal of Clinical Investigation·Ye ChenMichael Andreeff
May 21, 2013·Nature Biotechnology·El-ad David AmirDana Pe'er
Sep 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesMark Levis
Jan 20, 2015·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Lina HanMarina Konopleva
Jun 3, 2015·Blood·Byung-Sik ChoMarina Konopleva
Jan 30, 2016·Cancer Research·Weiguo ZhangMichael Andreeff
Mar 11, 2017·Leukemia·M AbrahamA Peled
Jul 25, 2017·Methods in Molecular Biology·Zhihong ZengMichael Andreeff
Feb 22, 2018·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xuejie JiangBing Z Carter
May 19, 2018·Haematologica·Weiguo ZhangMichael Andreeff
Dec 5, 2018·Blood·Eytan M SteinStéphane de Botton
May 16, 2019·Cancer Discovery·Christine M McMahonAlexander E Perl